Cargando…

Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients

BACKGROUND: Due to the waning humoral response after a two-dose SARS-CoV-2 mRNA vaccination, a third booster was recommended in hemodialyis patients. Data on a heterologous mRNA-vector regimen, which might improve immunogenicity, are very limited. METHODS: In this observational study 36 chronic hemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davidovic, Tamara, Schimpf, Judith, Abbassi-Nik, Armin, Stockinger, Richard, Sprenger-Mähr, Hannelore, Lhotta, Karl, Zitt, Emanuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261096/ https://www.ncbi.nlm.nih.gov/pubmed/35812459 http://dx.doi.org/10.3389/fimmu.2022.907615

Ejemplares similares

Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost
por: Davidovic, Tamara, et al.
Publicado: (2021)

Enhanced SARS-CoV-2 Antibody Response After a Third Heterologous Vector Vaccine Ad26COVS1 Dose in mRNA Vaccine-Primed Kidney Transplant Recipients
por: Schimpf, Judith, et al.
Publicado: (2022)

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
por: Zitt, Emanuel, et al.
Publicado: (2021)

Humoral Response in SARS-CoV-2 Convalescent Compared to Vaccinated Kidney Transplant Patients
por: Schimpf, Judith, et al.
Publicado: (2022)

De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis
por: Davidovic, Tamara, et al.
Publicado: (2021)

Acute Kidney Injury Treated with Dialysis outside the Intensive Care Unit: A Retrospective Observational Single-Center Study
por: Sprenger-Mähr, Hannelore, et al.
Publicado: (2016)

SARS-CoV-2 infection and recurrence of anti-glomerular basement disease: a case report
por: Winkler, Alexander, et al.
Publicado: (2021)

A hemodialysis patient with bone disease after pregnancy: a case report
por: Sprenger-Mähr, Hannelore, et al.
Publicado: (2019)

Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency
por: Zitt, Emanuel, et al.
Publicado: (2015)

Successful Treatment of Focal Segmental Glomerulosclerosis after Kidney Transplantation with Plasma Exchange and Abatacept in a Patient with Juvenile Rheumatoid Arthritis
por: Sprenger-Mähr, Hannelore, et al.
Publicado: (2016)

Treatment of Concurrent Thrombotic Thrombocytopenic Purpura and Graves' Disease: A Report on Two Cases
por: Lhotta, Karl, et al.
Publicado: (2018)

Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2
por: Rammauro, Florencia, et al.
Publicado: (2022)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2021)

Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients
por: Melin, Jan, et al.
Publicado: (2021)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
por: Miyazaki, Ryoichi, et al.
Publicado: (2023)

Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile
por: Díaz-Dinamarca, Diego A., et al.
Publicado: (2023)

Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination
por: Puro, Vincenzo, et al.
Publicado: (2021)

Kinetics of the humoral response 1-year following vaccination with BNT162b2 SARS-CoV-2 vaccine among maintenance hemodialysis patients
por: Wand, Ori, et al.
Publicado: (2022)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients
por: Broseta, José Jesús, et al.
Publicado: (2021)

Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2
por: Vogel, Emanuel, et al.
Publicado: (2022)

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2
por: Hayashi, Jackelinne Y., et al.
Publicado: (2022)

Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients
por: Broseta, José Jesús, et al.
Publicado: (2022)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
por: Prendecki, Maria, et al.
Publicado: (2021)

Humoral immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients
por: Anastasi, Emanuela, et al.
Publicado: (2022)

Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months
por: Lopera, Tulio J., et al.
Publicado: (2022)

PB2236: HUMORAL RESPONSE TO SARS-COV-2 VACCINATION WITH BNT162B2 COVID-19 MRNA IN PATIENTS WITH HAEMOGLOBINOPATHIES
por: Giatagantzidou, I., et al.
Publicado: (2022)

SARS-CoV-2 Specific Humoral Immune Responses after BNT162b2 Vaccination in Hospital Healthcare Workers
por: Golshani, Maryam, et al.
Publicado: (2022)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients
por: Berar-Yanay, Noa, et al.
Publicado: (2021)

Humoral response among patients with interstitial lung disease vaccinated with the BNT162b2 SARS-Cov-2 vaccine: a prospective cohort study
por: Pertzov, Barak, et al.
Publicado: (2022)

Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients: A multicenter prospective observational study
por: Haase, Michael, et al.
Publicado: (2022)

Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
por: Costard-Jäckle, Angelika, et al.
Publicado: (2022)

Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines
por: Atıcı, Serkan, et al.
Publicado: (2023)

Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study
por: Sim, Wooho, et al.
Publicado: (2023)

Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination
por: Appelman, Brent, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fg9i7bi63urpacuktvst5t74l2